The device (Gore Cardioform ASD Occluder) was approved based on the results of the Gore ASSURED Clinical Study of its performance in patients aged 2 to 84 years with atrial septal defects and ...

A Tampa doctor has used the new ASD device since November and has done the procedure for seven patients since then. St. Joseph's Children's Hospital in Tampa has started using a new device to operate ...

Walsh, KP, Tofeig M, Kitchiner DJ, Peart I, Arnold R. Comparison of the Sideris and Amplatzer septal occlusion devices. Am J Cardiol 1999 Mar 15; 933-6 Four atrial septal defect occluders (ASD) ...

The breakthrough device designation label noted the intended use of the platform will be applicable to patients between birth and age 21 years, with risk assessment for ASD to be conducted between ...

TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...

TCT 1307: Puncture and Deployment of a Second Trans-ASD Closure Device: A Treatment Strategy for Displaced ASD Occluder in a High Surgical Risk Patient With Complex Anatomy ...

The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

Atrial septal defect (ASD) and ventricular septal defect (VSD) are both conditions that involve incorrect blood flow within the heart.